Drugs / Penfluridol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07206563 | Oct 2025 → Oct 2027 expected | cervical small cell carcinoma, small cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Penfluridol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07206563 ↗ |
| Known as | MCN-JR-16,341 | ChEMBL registry synonym — accepted as the source's own label CHEMBL47050 ↗ |
| Known as | Micefal | ChEMBL registry synonym — accepted as the source's own label CHEMBL47050 ↗ |
| Known as | NSC-759179 | ChEMBL registry synonym — accepted as the source's own label CHEMBL47050 ↗ |
| Known as | R 16,341 | ChEMBL registry synonym — accepted as the source's own label CHEMBL47050 ↗ |
| Known as | Semap | ChEMBL registry synonym — accepted as the source's own label CHEMBL47050 ↗ |
| Modality | Small molecule | — CHEMBL47050 ↗ |
| Route | Oral | “Penfluridol, an oral antipsychotic drug, is used as monotherapy.” NCT07206563 ↗ |
| Target | DRD2 | “It targets DRD2, inhibits glycolysis, and induces apoptosis.” NCT07206563 ↗ |